RESUMEN
Sepsis is a life-threatening condition caused by a dysregulated host response to infection. The development of sepsis is associated with excessive nitric oxide (NO) production, which plays an important role in controlling vascular homeostasis. 7-nitroindazole (7-NI) is a selective inhibitor of neuronal nitric oxide synthase (NOS-1) with potential application for treating NO imbalance conditions. However, 7-NI exhibits a low aqueous solubility and a short plasma half-life. To circumvent these biopharmaceutical limitations, pegylated (NEPEG7NI) and non-pegylated nanoemulsions (NENPEG7NI) containing 7-NI were developed. This study evaluates the pharmacokinetic profiles and toxicological properties of 7-NI loaded into the nanoemulsions. After a single intravenous administration of the free drug and the nanoemulsions at a dose of 10 mg.kg-1 in Wistar rats, 7-NI was widely distributed in the organs. The pharmacokinetic parameters of Cmax, t1/2, and AUC0-t were significantly increased after administration of the NEPEG7NI, compared to both free 7-NI and NENPEG7NI (p < 0.05). No observable adverse effects were observed after administering the free 7-NI, NEPEG7NI, or NENPEG7NI in the animals after a single dose of up to 3.0 mg.kg-1. The results indicated that 7-NI-loaded nanoemulsions are safe, constituting a promising approach to treating sepsis.
Asunto(s)
Óxido Nítrico Sintasa , Sepsis , Ratas , Animales , Ratas Wistar , Óxido Nítrico Sintasa/metabolismo , Distribución Tisular , Indazoles/toxicidad , Indazoles/farmacocinética , Polietilenglicoles/toxicidad , Inhibidores Enzimáticos/farmacologíaRESUMEN
Biseugenol (1), a neolignan with antiprotozoal activity against Trypanosoma cruzi, was partially methylated, and the compound obtained - methyl biseugenol (2) - had its activity evaluated against the extracellular (trypomastigotes) and intracellular (amastigotes) forms of T. cruzi. It was observed that both compounds 1 and 2 exhibited similar effects against trypomastigotes (IC50 of 11.7 and 16.2 µM, respectively), whereas compound 2 displayed higher activity against amastigotes (IC50 = 8.2 µM) in comparison with biseugenol (IC50 = 15.4 µM). Additionally, reduced toxicity against NCTC cells for compound 2 was observed (CC50 > 200 µM), differently from compound 1 with CC50 = 58.0 µM. Aiming to understand better the molecular mechanism of the biological action of compound 2, the prodrug was incorporated into cellular membrane models constituted of Langmuir monolayers of the lipids dipalmitoylphosphatidylcholine (DPPC), dipalmitoylphosphatidylethanolamine (DPPE), dipalmitoylphosphatidylserine (DPPS), and dipalmitoylphosphatidylglycerol (DPPG). The lipid-drug interaction was inferred through tensiometry, surface potential, infrared spectroscopy (PM-IRRAS), and Brewster angle microscopy (BAM). The prodrug expanded DPPC and DPPG monolayers and condensed DPPE ones, as well as presented characteristic behaviors regarding the chemical structure of the lipid considering expansion-compression curves, surface potential-area isotherms, and stability of previously compressed monolayers to relevant-biological surface pressures. PM-IRRAS indicated a molecular disorder for DPPC and DPPS alkyl chains in the presence of the drug. BAM revealed the presence of domains in the DPPG and DPPE monolayers, which was probably induced by the prodrug. These data suggest, in general, that the lipid composition modulates the interaction of compound 2, whose results are expected to correlate to its trypanocidal activity, which involves the plasma membrane of T. cruzi as the primary target, i.e., the first barrier that the compound should encounter to interact with the microorganism.
Asunto(s)
Profármacos , Metilación , Membrana Celular/química , 1,2-Dipalmitoilfosfatidilcolina/química , Propiedades de SuperficieRESUMEN
Chagas disease, after more than a century after its discovery, is still a major public health problem. It is estimated that approximately 10 million people worldwide are infected with T. cruzi. However, the situation is more critical in Latin America and other regions where the disease is endemic. The largest number of cases occurs in Brazil, Argentina, and Mexico as more than 100 million people in these regions are located in areas with a high risk of contamination by the vector. The need for new therapeutic alternatives is urgent, as the available drugs have severe limitations such as low efficacy and high toxicity. From this scenario, in this work, we employed the virtual screening technique using cruzain and BDF2 as key biological targets for the survival of the parasite. Our objective was to identify potential inhibitors of T. cruzi trypomastigotes, which could be considered drug candidates against Chagas disease. For this, we employed different in silico methodologies and the obtained results were corroborated using in vitro biological assays. For the VS studies, a database containing synthetic compounds was simulated at the binding site of cruzain and BDF2. In addition, pharmacophoric models were constructed in the initial phases of VS, as well as other advanced analyses (molecular dynamics simulations, calculations of binding free energy, and ADME prediction) were carried out and the results allowed the selection of potential inhibitors of T. cruzi. Based on the obtained data, 32 different compounds commercially available were subjected to biological tests against the trypomastigote form of T. cruzi. As result, 11 of those compounds displayed significant activity against T. cruzi and can be considered potential candidates for the treatment of Chagas disease.
Asunto(s)
Enfermedad de Chagas , Tripanocidas , Trypanosoma cruzi , Humanos , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Simulación de Dinámica Molecular , Sitios de Unión , Dominios Proteicos , Tripanocidas/farmacología , Tripanocidas/uso terapéutico , Tripanocidas/químicaRESUMEN
Terpenes are one of the most abundant classes of secondary metabolites produced by plants and can be divided based on the number of isoprene units (C5 ) in monoterpenes (2 units-C10 ), sesquiterpenes (3 units-C15 ), diterpenes (4 units-C20 ), triterpenes (6 units-C30 ), etc. Chemically, triterpenes are classified based on their structural skeleton including lanostanes, euphanes, cycloartanes, ursanes, oleananes, lupanes, tirucallanes, cucurbitanes, dammaranes, baccharanes, friedelanes, hopanes, serratanes etc. Additionally, glycosylated (saponins) or highly oxidated/degraded (limonoids) triterpenes could be found in nature. The antiinflammatory effect and action as immunomodulators of these secondary metabolites have been demonstrated in different studies. This review reports an overview of articles published in the last 15 years (from 2006 to 2021 using PubMed and SciFinder database) describing the antiinflammatory effects of different triterpenes with their presumed mechanism of action, suggesting that triterpenes could be appointed as natural products with future pharmaceutical applicability.
Asunto(s)
Productos Biológicos , Saponinas , Triterpenos , Antiinflamatorios/farmacología , Productos Biológicos/química , Productos Biológicos/farmacología , Estructura Molecular , Plantas , Triterpenos/química , Triterpenos/farmacologíaRESUMEN
Considering the lack of effective and safe therapy for the treatment of Chagas disease, the antihypertensive drug manidipine (MDP) was in vitro evaluated against Trypanosoma cruzi. The bioenergetics of trypomastigotes was studied in the presence of the drug using fluorimetric and luminescent assays. Manidipine showed a potent antiparasitic activity, with IC50 values of 0.1 µM (intracellular amastigotes) and 3 µM (trypomastigotes), resulting in a promising selectivity index against the amastigotes (>1459). Using fluorimetric analysis, the drug showed depolarisation of the electric potential of the plasma membrane with no alteration of the permeability. A decrease in ATP levels suggested a bioenergetic alteration of the mitochondria, which was confirmed by the depolarisation of the mitochondrial membrane potential and a slight increase of the ROS levels. This is the first study to show the promising in vitro effectiveness of the antihypertensive MDP against T. cruzi, which may represent a candidate for future investigations in animal models.
Asunto(s)
Antihipertensivos/farmacología , Dihidropiridinas/farmacología , Reposicionamiento de Medicamentos , Nitrobencenos/farmacología , Piperazinas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Animales , Línea Celular , Macaca mulatta , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Tripanocidas/farmacología , Trypanosoma cruzi/metabolismoRESUMEN
Liposomes containing phosphatidylserine (PS) has been used for the delivery of drugs into the intramacrophage milieu. Leishmania (L.) infantum parasites live inside macrophages and cause a fatal and neglected viscerotropic disease, with a toxic treatment. Sertraline was studied as a free formulation (SERT) and also entrapped into phosphatidylserine liposomes (LP-SERT) against intracellular amastigotes and in a murine model of visceral leishmaniasis. LP-SERT showed a potent activity against intracellular amastigotes with an EC50 value of 2.5 µM. The in vivo efficacy of SERT demonstrated a therapeutic failure. However, when entrapped into negatively charged liposomes (-58 mV) of 125 nm, it significantly reduced the parasite burden in the mice liver by 89% at 1 mg/kg, reducing the serum levels of the cytokine IL-6 and upregulating the levels of the chemokine MCP-1. Histopathological studies demonstrated the presence of an inflammatory infiltrate with the development of granulomas in the liver, suggesting the resolution of the infection in the treated group. Delivery studies showed fluorescent-labeled LP-SERT in the liver and spleen of mice even after 48 h of administration. This study demonstrates the efficacy of PS liposomes containing sertraline in experimental VL. Considering the urgent need for VL treatments, the repurposing approach of SERT could be a promising alternative.
Asunto(s)
Antiprotozoarios/administración & dosificación , Leishmania donovani/efectos de los fármacos , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/parasitología , Liposomas , Fosfatidilserinas , Sertralina/administración & dosificación , Animales , Antiprotozoarios/química , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Inmunomodulación/efectos de los fármacos , Leishmania donovani/inmunología , Leishmaniasis Visceral/inmunología , Liposomas/química , Hígado/metabolismo , Hígado/parasitología , Hígado/patología , Macrófagos/efectos de los fármacos , Macrófagos/inmunología , Macrófagos/metabolismo , Macrófagos/parasitología , Ratones , Ratones Endogámicos BALB C , Fosfatidilserinas/administración & dosificación , Sertralina/química , Bazo/metabolismo , Bazo/parasitología , Bazo/patologíaRESUMEN
Epi-polygodial, a drimane sesquiterpene was isolated from Drimys brasiliensis (Winteraceae). This compound demonstrated high parasite selectivity towards Trypanosoma cruzi trypomastigotes (IC50â¯=â¯5.01⯵M) with a selectivity index higher than 40. These results were correlated with the effects observed when this compound was incorporated in cellular membrane models of protozoans, represented by Langmuir monolayers of dipalmitoylphosphoethanolamine (DPPE). Surface pressure-area isotherms showed that epi-polygodial expands DPPE monolayers at higher areas and condenses them at lower areas, which was attributed to the preferential interaction with the polar heads of the lipid. This mechanism of action could be corroborated with Polarization-Modulation Reflection-Absorption Spectroscopy and Brewster Angle Microscopy. These results pointed to the fact that the interaction of epi-polygodial with DPPE monolayers at the air-water interface affects the physical chemical properties of the mixed film, which may be important to comprehend the interaction of this drug with cellular membranes at the molecular level.
Asunto(s)
Membrana Celular/efectos de los fármacos , Drimys/química , Modelos Biológicos , Sesquiterpenos/farmacología , Tripanocidas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Aire , Relación Dosis-Respuesta a Droga , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Sesquiterpenos/química , Sesquiterpenos/aislamiento & purificación , Relación Estructura-Actividad , Tripanocidas/química , Tripanocidas/aislamiento & purificación , Agua/químicaRESUMEN
BACKGROUND: Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease. METHODS: In this work, we studied the activity of the antidepressant drug sertraline against Trypanosoma cruzi trypomastigotes and intracellular amastigotes of the Y and Tulahuen strains, and investigated its action mode using cell biology and in silico approaches. RESULTS: Sertraline demonstrated in vitro efficacy against intracellular amastigotes of both T. cruzi strains inside different host cells, including cardiomyocytes, with IC50 values between 1 to 10 µM, and activity against bloodstream trypomastigotes, with IC50 of 14 µM. Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. In silico approaches using chemogenomic target fishing, homology modeling and molecular docking suggested the enzyme isocitrate dehydrogenase 2 of T. cruzi (TcIDH2) as a potential target for sertraline. CONCLUSIONS: The present study demonstrated that sertraline had a lethal effect on different forms and strains of T. cruzi, by affecting the bioenergetic metabolism of the parasite. These findings provide a starting point for future experimental assays and may contribute to the development of new compounds.
RESUMEN
Drug repurposing has been an interesting and cost-effective approach, especially for neglected diseases, such as Chagas disease. Methods: In this work, we studied the activity of the antidepressant drug sertraline against Trypanosoma cruzi trypomastigotes and intracellular amastigotes of the Y and Tulahuen strains, and investigated its action mode using cell biology and in silico approaches. Results: Sertraline demonstrated in vitro efficacy against intracellular amastigotes of both T. cruzi strains inside different host cells, including cardiomyocytes, with IC50 values between 1 to 10 µM, and activity against bloodstream trypomastigotes, with IC50 of 14 µM. Considering the mammalian cytotoxicity, the drug resulted in a selectivity index of 17.8. Sertraline induced a change in the mitochondrial integrity of T. cruzi, resulting in a decrease in ATP levels, but not affecting reactive oxygen levels or plasma membrane permeability. In silico approaches using chemogenomic target fishing, homology modeling and molecular docking suggested the enzyme isocitrate dehydrogenase 2 of T. cruzi (TcIDH2) as a potential target for sertraline. Conclusions: The present study demonstrated that sertraline had a lethal effect on different forms and strains of T. cruzi, by affecting the bioenergetic metabolism of the parasite. These findings provide a starting point for future experimental assays and may contribute to the development of new compounds.(AU)
Asunto(s)
Trypanosoma cruzi , Técnicas In Vitro , Sertralina , Reposicionamiento de MedicamentosRESUMEN
The neglected tropical diseases Chagas disease and leishmaniasis affect together more than 20 million people living mainly in developing countries. The mainstay of treatment is chemotherapy, however the drugs of choice, which include benznidazole and miltefosine, are toxic and have numerous side effects. Safe and effective therapies are urgently needed. Marine alpha-pyrones have been previously identified as scaffolds with potential antiprotozoan activities. In this work, using a phenotypic screen, twenty-seven examples of 3-substituted 4-hydroxy-6-methyl alpha-pyrones were synthesized and their antiparasitic efficacy evaluated against Leishmania (L.) infantum and Trypanosoma cruzi in order to evaluate structure-activity relationships within the series. The mechanism of action and the in vivo efficacy of the most selective compound against T. cruzi were evaluated using different techniques. In vitro data indicated that compounds 8, 15, 25, 26 and 28 presented IC50 values in the range between 13 and 54 µM against L. infantum intracellular amastigotes. Among them, hexanoyl substituted pyrone 8 was the most selective and potent, with a Selectivity Index (SI) > 14. Fifteen of the alpha-pyrones were effective against T. cruzi trypomastigotes, with 3-undecanoyl (11) and 3-tetradecanoyl (12) substituted pyrones being the most potent against trypomastigotes, with IC50 values of 1 and 2 µM, respectively, and SI higher than 70. Using flow cytometry and fluorescent-based assays, pyrone 12 was found to induce hyperpolarization of the mitochondrial membrane potential of T. cruzi, without affecting plasma membrane permeability. An experimental acute phase-murine model, demonstrated that in vivo dosing of 12 (30 mg/kg/day; 5 days), had no efficacy at the first parasitemia onset of T. cruzi, but reduced the second onset by 55% (p < 0.05), suggesting a delayed action in BALB/c mice. Additionally, a histopathology study demonstrated no toxic effects to the treated mice. The finding that several 3-substituted alpha-pyrones have in vitro efficacy against both L. infantum and T. cruzi, and that one analogue exhibited moderate and non-toxic in vivo efficacy against T. cruzi is encouraging, and suggests that this compound class should be explored as long-term treatments in experimental Chagas disease.
Asunto(s)
Antiprotozoarios/farmacología , Leishmania infantum/efectos de los fármacos , Pironas/farmacología , Trypanosoma cruzi/efectos de los fármacos , Antiprotozoarios/síntesis química , Antiprotozoarios/química , Relación Dosis-Respuesta a Droga , Estructura Molecular , Pruebas de Sensibilidad Parasitaria , Pironas/síntesis química , Pironas/química , Relación Estructura-ActividadRESUMEN
Visceral leishmaniasis is a fatal parasitic neglected disease affecting 1.5 million people worldwide. Based on a drug repositioning approach, the aim of this work was to investigate the in vitro immunomodulatory potential of buparvaquone (BPQ) and to establish a safe regimen to evaluate the in vivo efficacy of BPQ entrapped by negatively charged nanoliposomes (BPQ-LP) in Leishmania infantum-infected hamsters. Small-angle X-ray scattering, dynamic light scattering, and the ζ-potential were applied in order to study the influence of BPQ on the liposome structure. Our data revealed that BPQ was located in the polar-apolar interface, snorkeling the polar region, and protected against aggregation inside the lipophilic region. The presence of BPQ also decreased the Z-average hydrodynamic diameter and increased the surface charge. Compared to intravenous and intramuscular administration, a subcutaneous route was a more effective route for BPQ-LP; at 0.4 mg/kg, BPQ-LP reduced infection in the spleen and liver by 98 and 96%, respectively. Treatment for 5 days resulted in limited efficacy, but 10 days of treatment resulted in an efficacy similar to that of a 15-day regimen. The nanoliposomal drug was highly effective, with a mean 50% effective dose of 0.25 mg/kg, reducing the parasite load in bone marrow by 80%, as detected using quantitative PCR analysis. In addition, flow cytometry studies showed that BPQ upregulated cytokines as tumor necrosis factor, monocyte chemoattractant protein 1, interleukin-10 (IL-10), and IL-6 in Leishmania-infected macrophages, eliminating the parasites via a nitric oxide-independent mechanism. This new formulation proved to be a safe and effective treatment for murine leishmaniasis that could be a useful candidate against visceral leishmaniasis.
Asunto(s)
Antiprotozoarios/farmacología , Factores Inmunológicos/farmacología , Leishmania infantum/efectos de los fármacos , Leishmaniasis Visceral/tratamiento farmacológico , Liposomas/química , Macrófagos/efectos de los fármacos , Naftoquinonas/farmacología , Administración Cutánea , Animales , Antiprotozoarios/química , Médula Ósea/efectos de los fármacos , Médula Ósea/inmunología , Médula Ósea/parasitología , Quimiocina CCL2/agonistas , Quimiocina CCL2/biosíntesis , Cricetinae , Modelos Animales de Enfermedad , Composición de Medicamentos/métodos , Factores Inmunológicos/química , Interleucina-10/agonistas , Interleucina-10/biosíntesis , Interleucina-6/agonistas , Interleucina-6/biosíntesis , Leishmania infantum/crecimiento & desarrollo , Leishmaniasis Visceral/inmunología , Leishmaniasis Visceral/parasitología , Liposomas/farmacocinética , Hígado/efectos de los fármacos , Hígado/inmunología , Hígado/parasitología , Macrófagos/inmunología , Macrófagos/parasitología , Masculino , Ratones , Nanoestructuras/administración & dosificación , Nanoestructuras/química , Naftoquinonas/química , Carga de Parásitos , Bazo/efectos de los fármacos , Bazo/inmunología , Bazo/parasitología , Electricidad Estática , Factor de Necrosis Tumoral alfa/agonistas , Factor de Necrosis Tumoral alfa/biosíntesisRESUMEN
BACKGROUND: The leishmanicidal action of tricyclic antidepressants has been studied and evidences have pointed that their action is linked to inhibition of trypanothione reductase, a key enzyme in the redox metabolism of pathogenic trypanosomes. Cyclobenzaprine (CBP) is a tricyclic structurally related to the antidepressant amitriptyline, differing only by the presence of a double bond in the central ring. This paper describes the effect of CBP in experimental visceral leishmaniasis, its inhibitory effect in trypanothione reductase and the potential immunomodulatory activity. METHODOLOGY/PRINCIPAL FINDINGS: In vitro antileishmanial activity was determined in promastigotes and in L. infantum-infected macrophages. For in vivo studies, L. infantum-infected BALB/c mice were treated with CBP by oral gavage for five days and the parasite load was estimated. Trypanothione reductase activity was assessed in the soluble fraction of promastigotes of L. infantum. For evaluation of cytokines, L. infantum-infected macrophages were co-cultured with BALB/c splenocytes and treated with CBP for 48 h. The supernatant was analyzed for IL-6, IL-10, MCP-1, IFN-γ and TNF-α. CBP demonstrated an IC50 of 14.5±1.1µM and an IC90 of 74.5±1.2 µM in promastigotes and an IC50 of 12.6±1.05 µM and an IC90 of 28.7±1.3 µM in intracellular amastigotes. CBP also reduced the parasite load in L. infantum-infected mice by 40.4±10.3% and 66.7±10.5% in spleen at 24.64 and 49.28 mg/kg, respectively and by 85.6±5.0 and 89.3±4.8% in liver at 24.64 and 49.28mg/kg, after a short-term treatment. CBP inhibited the trypanothione reductase activity with a Ki of 86 ± 7.7 µM and increased the ROS production in promastigotes. CBP inhibited in 53% the production of IL-6 in infected macrophages co-culture. CONCLUSION/SIGNIFICANCE: To the best of our knowledge, this study is the first report of the in vivo antileishmanial activity of the FDA-approved drug CBP. Modulation of immune response and induction of oxidative stress in parasite seem to contribute to this efficacy.
Asunto(s)
Amitriptilina/análogos & derivados , Antiprotozoarios/administración & dosificación , Leishmania infantum/efectos de los fármacos , Leishmaniasis Visceral/tratamiento farmacológico , Especies Reactivas de Oxígeno/metabolismo , Amitriptilina/administración & dosificación , Animales , Humanos , Interferón gamma/genética , Interferón gamma/inmunología , Interleucina-10/genética , Interleucina-10/inmunología , Interleucina-6/genética , Interleucina-6/inmunología , Leishmania infantum/genética , Leishmania infantum/metabolismo , Leishmaniasis Visceral/genética , Leishmaniasis Visceral/inmunología , Leishmaniasis Visceral/parasitología , Ratones , Ratones Endogámicos BALB C , Carga de Parásitos , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
The neglected tropical diseases Chagas disease and leishmaniasis affect together more than 20 million people living mainly in developing countries. The mainstay of treatment is chemotherapy, however the drugs of choice, which include benznidazole and miltefosine, are toxic and have numerous side effects. Safe and effective therapies are urgently needed. Marine alpha-pyrones have been previously identified as scaffolds with potential antiprotozoan activities. In this work, using a phenotypic screen, twenty-seven examples of 3-substituted 4-hydroxy-6-methyl alpha-pyrones were synthesized and their antiparasitic efficacy evaluated against Leishmania (L.) infantum and Trypanosoma cruzi in order to evaluate structure-activity relationships within the series. The mechanism of action and the in vivo efficacy of the most selective compound against T. cruzi were evaluated using different techniques. In vitro data indicated that compounds 8, 15, 25, 26 and 28 presented IC50 values in the range between 13 and 54 µM against L. infantum intracellular amastigotes. Among them, hexanoyl substituted pyrone 8 was the most selective and potent, with a Selectivity Index (SI) > 14. Fifteen of the alpha-pyrones were effective against T. cruzi trypomastigotes, with 3-undecanoyl (11) and 3-tetradecanoyl (12) substituted pyrones being the most potent against trypomastigotes, with IC50 values of 1 and 2 µM, respectively, and SI higher than 70. Using flow cytometry and fluorescent-based assays, pyrone 12 was found to
As doenças tropicais negligenciadas A doença de Chagas e a leishmaniose afetam juntas mais de 20 milhões de pessoas que vivem principalmente nos países em desenvolvimento. O suporte principal do tratamento é a quimioterapia, no entanto, os medicamentos de escolha, que incluem benznidazol e miltefosina, são tóxicos e têm inúmeros efeitos colaterais. Terapias seguras e eficazes são urgentemente necessárias. As alfa-pironas marinhas foram previamente identificadas como andaimes com potenciais atividades antiprotozoárias. Neste trabalho, usando uma tela fenotípica, sintetizaram-se 27 exemplos de 4-hidroxi-6-metil alfa-pironas 3-substituídas e avaliou-se sua eficácia antiparasitária contra Leishmania (L.) infantum e Trypanosoma cruzi para avaliar a estrutura relações de atividade dentro da série. O mecanismo de ação e a eficácia in vivo do composto mais seletivo contra T. cruzi foram avaliados por diferentes técnicas. Dados in vitro indicaram que os compostos 8, 15, 25, 26 e 28 apresentaram valores de IC50 na faixa entre 13 e 54 µM contra amastigotas intracelulares de L. infantum. Entre elas, a pirona 8 substituída com hexanoílo foi a mais seletiva e potente, com um índice de seletividade (SI)> 14. Quinze das alfa-pironas foram eficazes contra as tripomastigotas de T. cruzi, com 3-undecanoil (11) e 3-tetradecanoil ( 12) pironas substituídas sendo as mais potentes contra tripomastigotas, com valores de IC50 de 1 e 2 µM, respectivamente, e SI superiores a 70. Usando citometria de fluxo e ensaios à base de fluorescência, a pirona 12 foi encontrada para
Asunto(s)
Trypanosoma cruzi , Preparaciones Farmacéuticas , LeishmaniaRESUMEN
This study was to follow IFN-γ, TNF-α and IL-10 modulation of peripheral blood mononuclear cells (PBMC) from HIV/cerebral toxoplasmosis patients (CT) during specific treatment. The results were compared with two other groups: HIV patients that had CT at least one year before (P/CT) and individuals with chronic toxoplasmosis (CHR). Blood samples (63) collected from three groups were analyzed. CT, 15 patients (3 blood samples collected one day before Toxoplasma gondii treatment; 7 and 15days during the treatment). P/CT, 5 patients (one blood sample collected at least, one year after the treatment). CHR, 13 individuals with chronic toxoplasmosis (one blood sample). Cytokine levels were assessed by ELISA after PBMC stimulation with T. gondii antigen. CT patients had low IFN-γ; discrete increase at 7th and 15th days; and the levels were recovered in cured patients (P/CT). CT patients had high TNF-α in the beginning of the treatment. TNF-α levels decrease during the treatment (7th and 15th) and in those patients who were treated (P/CT). IL-10 levels were almost similar in CT and P/CT groups but low when compared with CHR individuals. The evolution of the infection was correlated to restoration of IFN-γ response and a decrease of the inflammation. The evaluation of the immune response can provide valuable information and better monitoring of patients during specific treatment.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/inmunología , Interferón gamma/sangre , Interleucina-10/sangre , Toxoplasmosis Cerebral/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/sangre , Infecciones Oportunistas Relacionadas con el SIDA/sangre , Infecciones Oportunistas Relacionadas con el SIDA/inmunología , Adulto , Antígenos de Protozoos/inmunología , Femenino , Humanos , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Toxoplasma/efectos de los fármacos , Toxoplasma/inmunología , Toxoplasmosis Cerebral/sangre , Toxoplasmosis Cerebral/inmunología , Adulto JovenRESUMEN
Three phenylpropanoid dimers (1-3) including two new metabolites were isolated from the extract of the twigs of Nectandra leucantha using antileishmanial bioassay-guided fractionation. The in vitro antiparasitic activity of the isolated compounds against Leishmania donovani parasites and mammalian cytotoxicity and immunomodulatory effects were evaluated. Compounds 1-3 were effective against the intracellular amastigotes within macrophages, with IC50 values of 26.7, 17.8, and 101.9 µM, respectively. The mammalian cytotoxicity, given by the 50% cytotoxic concentration (CC50), was evaluated against peritoneal macrophages. Compounds 1 and 3 were not toxic up to 290 µM, whereas compound 2 demonstrated a CC50 value of 111.2 µM. Compounds 1-3 also suppressed production of disease exacerbatory cytokines IL-6 and IL-10 but had minimal effect on nitric oxide production in L. donovani-infected macrophages, indicating that antileishmanial activity of these compounds is mediated via an NO-independent mechanism. Therefore, these new natural products could represent promising scaffolds for drug design studies for leishmaniasis.
Asunto(s)
Anisoles/aislamiento & purificación , Anisoles/farmacología , Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/farmacología , Factores Inmunológicos/aislamiento & purificación , Factores Inmunológicos/farmacología , Lauraceae/química , Leishmaniasis/tratamiento farmacológico , Fenilpropionatos/aislamiento & purificación , Fenilpropionatos/farmacología , Animales , Anisoles/química , Antiprotozoarios/química , Brasil , Factores Inmunológicos/química , Concentración 50 Inhibidora , Interleucina-10 , Interleucina-6 , Leishmania donovani/efectos de los fármacos , Macrófagos Peritoneales/efectos de los fármacos , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Estructura Molecular , Óxido Nítrico/metabolismo , Fenilpropionatos/química , Tallos de la Planta/químicaRESUMEN
Drug repositioning has been considered a promising approach to discover novel treatments against neglected diseases. Among the major protozoan diseases, leishmaniasis remains a public health threat with few therapeutic alternatives, affecting 12 million people in 98 countries. In this study, we report the in vitro antileishmanial activity of the imidazole drugs clotrimazole, and for the first time in literature, econazole and bifonazole and their potential action to affect the regulation of reactive oxygen species (ROS) of the parasites. The lethal action of the imidazoles was investigated using spectrofluorimetric techniques to detect ROS content, plasma membrane permeability, and mitochondrial membrane potential. The imidazoles showed activity against L. (L.) infantum chagasi promastigotes with IC50 values in a range of 2-8 µM; econazole was also effective against Leishmania intracellular amastigotes, with an IC50 value of 11 µM, a similar in vitro effectiveness to miltefosine. Leishmania promastigotes rapidly up-regulated the ROS release after incubation with the imidazoles, but econazole showed a marked increase in ROS content of approximately 1,900 % higher than untreated parasites. When using SYTOX(®) Green as a fluorescent probe, the imidazoles demonstrated considerable interference in plasma membrane permeability at the early time of incubation; econazole resulted in the higher influx of SYTOX(®) Green at 60 min. Despite cellular alterations, no depolarization could be observed to the mitochondrial membrane potential of Leishmania until 60 min. The lethal action of econazole involved strong permeabilization of plasma membrane of promastigotes, with an overloaded ROS content that contributed to the death of parasites. Affecting the ROS regulation of Leishmania via small molecules would be an interesting strategy for new drugs.
Asunto(s)
Antiprotozoarios/farmacología , Imidazoles/farmacología , Leishmania infantum/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismo , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Permeabilidad de la Membrana Celular/efectos de los fármacos , Clotrimazol/farmacología , Econazol/farmacología , Leishmania/efectos de los fármacos , Leishmania/metabolismo , Leishmania infantum/metabolismo , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacosRESUMEN
This study investigated how Toxoplasma gondii excretory-secretory antigens (ESA) stimulate the humoral and cellular response in infected hosts. We evaluated IFN-γ, IL-4 TNF-α, and IL-10 levels as well as humoral response of ESA-immunized AS/n mice. T. gondii lysate antigen (TLA), a crude antigen, was used in all experiments to evaluate the immune response. Chronic infected and naive mice were used as control groups, since the immune response is well known. The challenge experiments showed the parasitemia levels, determined by real time PCR and survival index. The naive group had early mortality and higher parasitemia than the ESA-immunized mouse group. In addition the chronic infected group had no parasitemia and mortality. Both ESA-immunized and chronic infected mice produced a similar level of IFN-γ and TNF-α. ESA, also, activated cells from immunized mice to produce IL-4 and IL-10 in lower levels compared to those cells collected from chronic mice but sufficient to modulate IFN-γ and TNF-α synthesis, preventing an excessive immune response that could cause extensive inflammation and host tissue damage. After 6 weeks, ESA-immunized mice had low IgM and IgG2a levels and high IgG1 levels. Purified anti-ESA IgG were able to opsonize tachyzoites (RH strain), and mice that received these parasites had lower parasitemia, and mortality was delayed 48 h, compared with the same results from those receiving parasites opsonized with IgG purified from naive mice. The protective immune response in the chronic infection was efficient in protecting the host against infection caused by other T. gondii strain and ESA participate in stimulating the host humoral and cellular responses. The immunization assays showed that ESA can elicit high IgG1, IFN-γ and TNF-α production and, a lower amount of IgM, IgG2, IL-10 and IL-4, suggesting a mixed Th1/Th2 profile.
Asunto(s)
Anticuerpos Antiprotozoarios/sangre , Antígenos de Protozoos/inmunología , Citocinas/metabolismo , Leucocitos Mononucleares/inmunología , Vacunas Antiprotozoos/inmunología , Toxoplasmosis Animal/prevención & control , Vacunación/métodos , Animales , Antígenos de Protozoos/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Ratones , Carga de Parásitos , Parasitemia/prevención & control , Vacunas Antiprotozoos/administración & dosificación , Reacción en Cadena en Tiempo Real de la Polimerasa , Análisis de SupervivenciaRESUMEN
Vero cells have been used successfully in Toxoplasma gondii maintenance. Medium supplementation for culture cells with fetal bovine serum is necessary for cellular growth. However, serum in these cultures presents disadvantages, such as the potential to induce hypersensitivity, variability of serum batches, possible presence of contaminants, and the high cost of good quality serum. Culture media formulated without any animal derived components, designed for serum-free growth of cell lines have been used successfully for different virus replication. The advantages of protozoan parasite growth in cell line cultures using serum-free medium remain poorly studied. Thus, this study was designed to determine whether T. gondii tachyzoites grown in Vero cell cultures in serum-free medium, after many passages, are able to maintain the same antigenic proprieties as those maintained in experimental mice. The standardization of Vero cell culture in serum-free medium for in vitro T. gondii tachyzoite production was performed establishing the optimal initial cell concentration for the confluent monolayer formation, which was 1×10(6) Vero cell culture as initial inoculum. The total confluent monolayer formatted after 96 h and the best amount of harvested tachyzoites was 2.1×10(7) using parasite inoculum of 1.5×10(6) after 7 days post-infection. The infectivity of tachyzoites released from Vero cells maintained in serum-free medium was evaluated using groups of Swiss mice infected with cell-culture tachyzoites. The parasite concentrations were similar to those for mice infected with tachyzoites collected from other infected mice. The data from both in vivo and in vitro experiments showed that in at least 30 culture cell passages, the parasites maintained the same infectivity as maintained in vivo. Another question was to know whether in the several continued passages, immunogenic progressive loss could occur. The nucleotide sequences studied were the same between the different passages, which could mean no change in their viability in the lysate antigen. Thus, the antigen production by cell culture has clear ethical and cost-saving advantages. Moreover, the use of culture media formulated without any human or animal derived components, designed for serum-free growth of cell lines, successfully produced tachyzoites especially for antigen production.
Asunto(s)
Antígenos de Protozoos/biosíntesis , Toxoplasma/inmunología , Animales , Antígenos de Protozoos/análisis , Antígenos de Protozoos/genética , Antígenos de Protozoos/inmunología , Secuencia de Bases , Chlorocebus aethiops , Medio de Cultivo Libre de Suero , ADN Protozoario/química , ADN Protozoario/aislamiento & purificación , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Sueros Inmunes/inmunología , Ratones , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Proteínas Protozoarias/genética , Alineación de Secuencia , Pase Seriado , Organismos Libres de Patógenos Específicos , Toxoplasma/genética , Toxoplasma/crecimiento & desarrollo , Células VeroRESUMEN
A toxoplasmose, em suas várias formas clínicas, é um problema de saúde pública e o estudo de antígenos (Ags) com potencial uso em diagnóstico e composição de vacinas, um desafio. Culturas de células vêm sendo usadas em substituição a animais na produção destes antígenos. O presente estudo buscou primeiramente avaliar e otimizar a produção de dois antígenos provenientes de taquizoítos: antígeno lisado de taquizoítos (ALT) e antígeno excretado/secretado (ESA) obtidos em células VERO sem adição de soro fetal bovino (SFB). Foram analisadas condições ideais de cultura, infectividade, presença de mutações genômicas e imunogenicidade em material obtido durante 30 passagens em cultura. Para tanto foram usadas técnicas de inoculação in vivo e in vitro, biologia molecular (PCR e sequenciamento) e ensaio imunoenzimático (ELISA). Os resultados obtidos mostraram mesma eficiência da cultura celular em relação a animais e culturas com adição de SFB para a produção destes Ags. Ainda, não houve alteração na composição antigênica comprovada pela ausência de mutações durante as passagens em cultura. Para avaliar a capacidade de ESA em induzir resposta imune humoral e celular e proteger os animais de desafio com cepa virulenta de T. gondii, foram utilizados camundongos A/Sn divididos em três grupos (5 animais cada): A: imunizado com 4 doses de ESA (20μg com ALUM), B infectado com a cepa ME-49 (controle positivo) e C, inoculado com ALUM (controle negativo). Usando ELISA, foram dosados nos soros desses animais anticorpos das diferentes classes de imunoglobulinase com células de baço estimuladas com Ags e mitógenos, dosadas citocinas em sobrenadante de cultura. Os resultados obtidos mostraram uma produção aumentada de anticorpos da classe IgG1 e de citocinas IFN-γ e TNF-α e baixa produção de IgM e IgG2a, IL10 e IL4 em animais imunizados com ESA em relação ao grupo controle positivo. Este mostrou...
Asunto(s)
Animales , Ratones , Antígenos , Inmunidad Celular , Inmunidad Humoral , Inmunización , ToxoplasmaRESUMEN
Objetivos: analisar experimentalmente a evolução da resposta imune humoral nas fases aguda e crônica recente da infecção por Toxoplasma gondii e sua correlação com o parasitismo sanguíneo. Métodos: foram analisados, por 60 dias, 10 camundongos fêmeas da linhagem AS/n infectados, por via oral, com 10 cistos por animal da cepa ME-49 de Toxoplasma gondii. As coletas de sangue foram feitas a cada 3-4 dias. O parasitismo sanguíneo foi avaliado pela reação em cadeia da polimerase e os títulos de anticorpos por enzimaimunoensaio e imunofluorescência indireta. Resultados: a reação em cadeia da polimerase foi positiva em amostras com intervalos de aproximadamente 7 dias até o 28º dia, e a seguir, negativas até o 60º dia. Os soros avaliados pela imunofluorescência indireta apresentaram anticorpos IgM após o 7º dia, com pico entre o 18º e 27º dia. Após o primeiro mês os títulos foram baixos até o 60º dia. Anticorpos IgG surgiram no 14º dia e persistiram em altos títulos até o 60º dia. A cinética dos anticorpos IgG, bem como a avidez destes, demonstrou que os níveis de anticorpos aumentaram a partir do 14º dia e as porcen-tagens de avidez evoluíram com pico máximo após 28 dias, estabelecendo-se então a fase crônica da infecção. Conclusões: os dados aqui demonstrados enfatizam que taquizoítos podem estar presentes na circulação sanguínea durante toda a fase aguda da toxoplasmose, mesmo que já se tenha instalado a resposta imune protetora.
Aims: To analyze experimentally the humoral immune response in acute and recent chronic infections by Toxoplasma gondii and its correlation with the blood parasitism. Methods: Ten female mice AS/n inbred strain orally infected with 10 cysts per animal from T. gondii ME-49 strain were evaluated during 60 days. Blood collections were made in each 3-4 days. Blood parasitism was evaluated by polymerase chain reaction, and antibody titres by enzyme-linked immunosorbent assay and indirect immunofluorescence. Results: Positive polymerase chain reaction was detected around seven day-intervals until the 28th day and was negative after the 30th day pos-infection. Sera assayed by immunofluorescence presented IgM antibodies after the 7th day of infection and high titers were found between the 18th and 27th day. After 30 days, IgM titers were low until the 60th day. IgG antibodies were produced around the 14th day and were high until the 60th day. The avidity and kinetic exhibited by IgG antibody levels increased from the 14th day and the avidity percents increased with maximum peak after 28 days, establishing the chronic infection. Conclusions: These data emphasize that tachyzoites can be detected in blood during the acute phase of toxoplasmosis, even though the protective immune response was already developed.